University hospitals leuven in belgium outlines their menu expansion plans for optical genome mapping as one of their primary analyses in leukemias & lymphomas and genetic disease

San diego, dec. 23, 2021 (globe newswire) -- bionano genomics, inc. (bngo), pioneer of optical genome mapping (ogm) solutions on the saphyr® system and provider of the leading software solutions for visualization, interpretation and reporting of genomic data, today announced that university hospitals leuven in belgium, after previously receiving its accreditation from the belgian accreditation body (belac) for using ogm in analysis of acute lymphoblastic leukemia (all), is expanding its belac-accredited menu to include acute myeloid leukemia (aml), chronic lymphocytic leukemia (cll) and facioscapulohumeral muscular dystrophy (fshd).
BNGO Ratings Summary
BNGO Quant Ranking